comprehensive -WSS

comprehensive

author：comprehensive 2025-08-26 01:32:46 - browse：128

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： What we know about the American soldier detained in North Korea

focus

explore

WSS

US soldier in North Korean custody after crossing DMZ line

Flagship, Pfizer team up in deal worth up to $7 billion

FDA poised to publish guidelines for clinical trial diversity

US soldier in North Korean custody after crossing DMZ line

US soldier in North Korean custody after crossing DMZ line

US soldier in North Korean custody after crossing DMZ line

knowledge

comprehensive

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Investigation reveals sickle cell patients pressured into sterilizations

Anesthesiologist group: stop taking Ozempic before surgery

15 die by electrocution after transformer explodes in northern India

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Reports of telehealth's death have been greatly exaggerated

United colonoscopy coverage change 'may cost lives,' doctors say

A look at other Americans who have crossed into North Korea over the years

In age of alternative facts, a scholarly course on calling out crap

BridgeBio heart drug succeeds in pivotal study

focus

Digital health: a case of mistaken identity

ASCO eve: Let’s set the table for this year's meeting

Addressing health care workers' trauma can help fight burnout

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

As a primary care physician, here's how I hope to partner with AI

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

focus

knowledge

explore

hotspot